STI Stock Trade Intelligence
ILA

ISLAND PHARMACEUTICALS LIMITED

Health Care · ASX:ILA
$0.2950
0.00%
Market cap
$87M
Turnover
$11,093
Last price
$0.2950
Day change
0.00%
Announcements
22
Range, past year
Open 0.525 · Low 0.130 · Now 0.295 · High 0.630
Open ILA in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

ILA momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
31/100
Wyckoff phase
Accumulation8d
Trend stage
Neutral
1 Day
+0.0%
1 Week
-7.8%
1 Month
-14.5%
1 Year
-30.6%
RSI
40
Avg daily range
7.1%

ISLAND PHARMACEUTICALS LIMITED scores 31 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.92 — highly linear uptrend
Points to watch
  • 60d drawdown -42.6%
  • High volatility (ATR 7.1%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
ILA appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

ILA announcements

Recent price-sensitive releases.
  • 2026-11-04 NHP Surgeries Commence Ahead of Galidesivir Marburg Study Progress Report
  • 2026-10-26 Quarterly Appendix 4C and Activities Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-19 USAMRIID Marburg study advances towards dosing Progress Report
  • 2026-10-02 Galidesivir GMP manufacturing commences Progress Report
  • 2026-08-31 Pivotal Marburg data secured for Galidesivir FDA pathway Progress Report
  • 2026-08-26 Preliminary Final Report Preliminary Final Report
  • 2026-08-21 Island boosts Galidesivir supply as Ebola surges Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.